NBIX241220C200000
- 2.27
- 0.000.00%
Neurocrine Biosciences Newsroom
"Laggard" Stocks With Expanding FCF Margins and Attractive FCF Yields – Goldman
Investors in Neurocrine Biosciences (NASDAQ:NBIX) Have Seen Notable Returns of 53% Over the Past Three Years
Neurocrine Biosciences To Present At Evercore HealthCONx Conference; Webcast At 10:50 AM ET
Screening For Black Friday Bargains In The Stock Market
Why Neurocrine Biosciences (NBIX) Is the Most Profitable Pharmaceutical Stock Right Now?
Neurocrine (NBIX) Receives a Hold From RBC Capital
Short Stock Ideas From Each Sector With Earnings Quality in the Bottom 20%
Neurocrine Biosciences to Participate at Investor Conferences in December
Trending Stocks Today | ZenaTech up 7.47% Post-Market
Congenital Adrenal Hyperplasia Landscape Research 2024: Comprehensive Insights About 8+ Pipeline Drugs Featuring Neurocrine Biosciences, Spruce Biosciences, Lundbeck, and HBM Alpha Therapeutics
Stifel Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $166
Neurocrine Biosciences To Present At Jefferies London Healthcare Conference; Webcast At 8:30 AM ET
Neurocrine Biosciences To Present At Stifel Healthcare Conference; Webcast At 10:55 AM ET
US Manufacturing Index Rises To 43, Highest Since 2020
Piper Sandler Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Raises Target Price to $160
Neurocrine Biosciences To Present At UBS Global Healthcare Conference; Webcast At 4:15 PM ET
AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio
AbbVie's Disappointing Schizophrenia Drug Trial Bodes Well for Rival Bristol Myers, Analysts Say
Oppenheimer Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $192
Jefferies Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Cuts Target Price to $158